Virios Therapeutics Commences Mid-Stage Long-COVID Study
Virios Therapeutics (Nasdaq: VIRI) has initiated patient dosing in its exploratory Long-COVID trial evaluating IMC-2 (valacyclovir + celecoxib).
Virios Therapeutics’ Announced Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM"), today announced commencement of enrollment in its exploratory Long-COVID trial.
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022…
By David Bautz, PhD
NASDAQ:VIRI
READ THE FULL VIRI RESEARCH REPORT
VIRI: Testing Combination Antiviral Therapy to Treat Long COVID…
By David Bautz, PhD
NASDAQ:VIRI
READ THE FULL VIRI RESEARCH REPORT
Virios Therapeutics Q4 EPS $(0.54) Beats $(0.67) Estimate
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.67) by 19.4 percent. This is a 56.8 percent increase over losses of $(1.25) per share from
Virios Therapeutics Announces Research Collaboration Exploring The Potential Of Combination Antiviral Therapy For Treating Long COVID
Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today a
Benzinga Announces This Week’s All Access Guests
Benzinga is thrilled to announce the guest lineup for our next All Access show, presented by RedChip, set to air Friday, January 28 at 9:15 am ET.
The Lineup
9:15 am: Opening Remarks with RedChip